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Objectives This study sought to assess the incidence, predictors, and outcome of drug-eluting stent (DES) thrombosis in
real-world clinical practice.
Background The DES thromboses in randomized trials could not be comparable to those observed in clinical practice, fre-
quently including off-label indications.
Methods We designed a large-scale, nonindustry-linked multicentered registry, with 20 centers in Spain. The participant
centers provided follow-up data for their patients treated with DES, reporting a detailed standardized form in the
event of any angiography-documented DES-associated thrombosis occurring.
Results Of 23,500 patients treated with DES, definite stent thrombosis (ST) developed in 301: 24 acute, 125 subacute, and
152 late. Of the late, 62 occurred1 year (very late ST). The cumulative incidence was 2% at 3 years. Antiplatelet
treatment had been discontinued in 95 cases (31.6%). No differences in incidences were found among stent types.
Independent predictors for subacute ST analyzed in a subgroup of 14,120 cases were diabetes, renal failure, acute
coronary syndrome, ST-segment elevation myocardial infarction, stent length, and left anterior descending artery
stenting, and for late ST were ST-segment elevation myocardial infarction, stenting in left anterior descending artery,
and stent length. Mortality at 1-year follow-up was 16% and ST recurrence 4.6%. Older age, left ventricular ejection
fraction 45%, nonrestoration of Thrombolysis In Myocardial Infarction flow grade 3, and additional stenting were
independent predictors for mortality.
Conclusions The cumulative incidence of ST after DES implantation was 2% at 3 years. No differences were found among stent
types. Patient profiles differed between early and late ST. Short-term prognosis is poor, especially when restoration of
normal flow fails. (J Am Coll Cardiol 2008;51:986–90) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.057t
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Gortality rates, myocardial infarction, and stent throm-
osis (ST) with drug-eluting stents (DES) in the com-
ined analyses of multiple randomized trials are compa-
able to those observed with bare-metal stents (BMS),
lthough patients included in these trials had a low risk
rofile (1,2).
rom the *Hospital Marques de Valdecilla, Santander; †Hospital Clinico San Carlos,
adrid; ‡Hospital 12 de Octubre, Madrid; §Hospital Gregorio Marañon, Madrid;
Hospital do Meixoeiro, Vigo; ¶Hospital Virgen de la Arrixaca, Murcia; #Hospital
entral de Asturias, Oviedo; **Hospital Juan Canalejo, La Coruña; ††Hospital
undacio´n Alcorcon, Alcorcon; ‡‡Hospital de Leon, Leon; §§Hospital Virgen de la
ictoria, Malaga;  Hospital Clı´nico, Valencia; ¶¶Hospital General, Alicante; aInitial clinical practice registries provided data on
hrombosis rates, frequently including off-label indica-
ions for DES. In these studies the incidence of stent
hrombosis was around 1.3%, with a late thrombosis rate
f 0.35% to 0.8% depending on the definitions applied,
nd different predictors for thrombosis were identi-
#Hospital Son Dureta, Palma de Mallorca; ***Policlı´nica Guipúzcoa, San Sebastia´n;
††Hospital Miguel Servet, Zaragoza; ‡‡‡Hospital Clinico, Salamanca; §§§Hospital
e Galdacano, Bilbao;   Hospital Infanta Cristina, Badajoz; and the ¶¶¶Hospital
ermans Trias i Pujol, Badalona, Spain.
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March 11, 2008:986–90 Nationwide Study on DES Thrombosised (3– 6). Nevertheless, there is a paucity of data on the
agnitude of DES-associated thrombosis in standard
ardiology practice, its incidence years after implantation,
nd the predisposing factors, specifically for late ST.
The current study was designed as a multicenter industry-
ndependent registry with the aim of resolving these areas of
oubt regarding DES thrombosis in real-world cardiology
ractice.
ethods
his is an industry-independent prospective registry. All
oordination between the 20 participating centers across
pain, the adjudication process, and analyses were per-
ormed centrally at the Hospital Universitario Marques de
aldecilla in Santander.
atient selection. Since the introduction of DES in Spain
n June 2002, its penetration has increased from 5% in 2002
o 59% in 2006 and has varied widely in different cen-
ers (7). All of the participating centers were required to fill
n a detailed standardized form in the event of any
ngiographically-documented DES-associated thrombosis oc-
urring since the introduction of DES. Patients gave informed
onsent for the inclusion of their data in the registry, and
nonymity was guaranteed.
efinitions. Stent thrombosis was considered to have oc-
urred when confirmed by angiography: either Thrombolysis
n Myocardial Infarction flow grade 0 or 1 or the presence of
ow-limiting thrombus (Thrombolysis In Myocardial Infarc-
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Figure 1 Cumulative Incidence of ST
A Kaplan-Meier curve shows the survival free of definite stent thrombosis (ST)
for the overall cohort and the subsequent cumulative incidence of ST. This inci-
dence was 1.2%, 1.6%, and 2% at 1, 2, and 3 years, respectively.ion flow grade 1 or 2) occurring at any time after stent
v
implantation. Acute coronary syn-
rome would need to have been
resent for those cases with ST1
onth post-procedure. This was
efined as the presence of at least 1
f the following: new onset of
ypical chest pain at rest20 min,
ew acute ischemic electrocardio-
raphic changes, or typical rise and
all in cardiac biomarkers.
ollow-up. Clinical follow-up
ata were obtained from the hos-
ital registries and medical
ecords in which the data from
he scheduled visits of patients,
ospital admissions, and proce-
ural reports are collected. The appropriate medical records
nd discharge summaries were solicited for patients who
ad suffered events at another hospital.
tatistical analysis. Continuous variables are presented
s mean  standard deviation or as median followed by
5th to 75th percentile. Categorical variables are ex-
ressed as percentages. Continuous variables were com-
ared with the Student t test if the data followed a
ormal distribution and with Wilcoxon tests if the data
ere skewed. Categorical variables were compared with
he chi-square square test or the Fisher exact test where
ndicated. We planned ahead to perform a multivariate
nalysis in a subgroup within the total cohort of patients
at least from 6 centers). Multivariate analyses were done
linical, Angiographic, and Proceduralharacteristics of Patients With and Withoutocumented ST
Table 1
Clinical, Angiographic, and Procedural
Characteristics of Patients With and Without
Documented ST
No ST
(n  23,199)
ST
(n  301) p Value
Age, yrs 63  11 60.4  12 0.0001
Female 5,568 (24%) 71 (23.6%) 0.92
Diabetes 6,964 (30%) 93 (30.8%) 0.81
Hypertension 10,790 (46.5%) 148 (49.2%) 0.38
Hypercholesterolemia 10,555 (45%) 145 (48.2%) 0.29
Renal failure 696 (3%) 15 (5%) 0.06
LVEF, % 57  11 50.9  12 0.0001
ACS 13,306 (57.4%) 247 (82%) 0.0001
STEMI 2,540 (11%) 112 (37.2%) 0.0001
LAD lesion 11,656 (50.3%) 220 (73%) 0.0001
Total occlusion 2,313 (10%) 63 (21%) 0.0001
Restenosis 1,855 (8%) 26 (8.6%) 0.74
Bifurcation (2 stents) 694 (3%) 13 (4.3%) 0.25
Stent length, mm 20  7 25.3  14.6 0.0001
Stent diameter, mm 2.94  0.3 2.83  0.36 0.0001
Abciximab 3,424 (14.8%) 80 (26.5%) 0.0001
Number of lesions
treated per patient
1.45  0.7 1.53  0.8 0.049
alues are mean  standard or n (%).
ACS  acute coronary syndrome; LAD  left anterior descending coronary artery; LVEF  left
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
LAD  left anterior
descending artery
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarctionentricular ejection fraction; ST stent thrombosis; STEM
nfarction.I  ST-segment elevation myocardial
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Nationwide Study on DES Thrombosis March 11, 2008:986–90sing those variables with p  0.25 in the univariate
nalysis, but variable of antiplatelet therapy discontinua-
ion was not included because the data were not available
or all cases without ST. A stepwise Cox proportional
azards model was used to identify independent predic-
ors of mortality and recurrent thrombosis after the ST
vent. Kaplan-Meier survival curves analyses were used to
how the cumulative incidence of ST and in comparing
ortality and recurrent thrombosis of late versus early
vents. All probability values were 2-sided, and values of
 0.05 were considered statistically significant. The
tatistical package SPSS 11.0 (SPSS Inc., Chicago, Illi-
ois) was used throughout.
haracteristics of the Patientsith Acute/Subacut and Late ST
Table 2 Characteristics of the PatientsWith Acute/Subacute and Late ST
Acute/Subacute ST
(n  149)
Late ST
(n  152) p Value
Age, yrs 62.5  11 58.4  13 0.003
Female 45 (30%) 26 (17%) 0.011
Diabetes 60 (40%) 33 (21.7%) 0.0009
Renal failure 11 (7.4%) 4 (2.6%) 0.099
Hyperlipidemia 64 (43%) 81 (53.3%) 0.10
Hypertension 79 (53%) 69 (45.4%) 0.20
ACS 127 (85%) 120 (79%) 0.22
STEMI 57 (38%) 55 (36.2%) 0.80
EF 50  12 51.7  11 0.21
Restenosis 12 (8%) 14 (9.2%) 0.86
Total occlusion 26 (17.4%) 37 (24.3%) 0.17
Bifurcation (2 stents) 9 (6%) 4 (2.6%) 0.24
LAD 107 (72%) 113 (74.3%) 0.79
Multiple lesions treated 45 (30%) 57 (37.5%) 0.21
Abciximab 34 (23%) 46 (30.2%) 0.19
Stent length 25.8  14 24.8  14 0.52
Stent diameter 2.79  0.3 2.87  0.38 0.044
Suboptimal result* 39 (26%) 16 (10.5%) 0.0008
Stent underexpansion 29 (19%) 14 (9.2%) 0.022
Median time to stent
thrombosis
6 (2 to 10) 287 (168 to 552)
alues are presented as mean  standard deviation, n (%), or median (interquartile range). *Any
f the following: stent underexpansion noted by angiography defined as in-stent residual stenosis
10%; final Thrombolysis In Myocardial Infarction flow grade 3; noncovered dissection at stent
argins; significant disease in the adjacent reference segments defined as a stenosis 25%.
EF  ejection fraction; other abbreviations as in Table 1.
ntiplatelet Treatment at the Time of ST
Table 3 Antiplatelet Treatment at the Time of ST
Antiplatelet Administered
Acute/Subacute ST
(n  149)
Late ST
(n  90
ASA  clopidogrel 110 (74%) 20 (22%
ASA alone 15 (10%) 54 (60%
Clopidogrel alone 11 (7.4%) 3 (3.3%
Coumadin 0 1 (1.1%
No antiplatelet therapy 11 (7.4%) 11 (12.2
Early dual therapy cessation 38 (25.5%) 30 (33.3
Cessation of ASA monotherapy 0 7 (7.7%
alues are presented as n (%). Early dual therapy cessation was the discontinuation of clopid
iscontinuation of ASA once the prescribed dual-therapy period had passed. *Acute/subacute versus late
ASA  aspirin; other abbreviations as in Table 1.esults
etween June 2002 and January 2007, a total of 23,500
atients were treated with 34,075 DES: 37% with
irolimus-eluting stents (SES) and 63% with paclitaxel-
luting stents (PES) in 20 centers. With a median follow-up
f 22 months (11 to 32, 25th percentile and 75th percentile,
espectively), 301 patients (1.28%) had documented ST:
4 (8%) were acute (24 h), 125 (41.5%) were subacute (24
to 30 days), 90 (30%) were late (1 month to 12 months),
nd 62 (20.6%) were very late (1 year). Figure 1 shows
he cumulative survival free of ST. Cumulative incidence
t 3 years was 2% without differences between stent
ypes (1.97% for PES and 2.03% for SES; p  0.8). The
linical characteristics of the groups with and without
hrombosis are described in Table 1. The clinical and
rocedural characterization of the ST types are summarized
n Table 2. Compared with the acute/subacute ST, the
ases with late ST were younger men, with a lower
ncidence of diabetes, with larger vessels and less frequent
uboptimal angiographic outcomes. Antiplatelet treat-
ent at the time of the event is presented in Table 3. At
ischarge from hospital, the duration of combined anti-
latelet therapy was 8  3 months. Overall, 95 pa-
ients (31.6%) were not taking the prescribed antiplatelet
herapy. The reason for treatment cessation was bleeding
n 12 patients, surgical intervention in 11, allergic reac-
ion to antiplatelet drugs in 6, and noncompliance in 66
atients. Among those with late ST, 70 patients had ST
fter properly completing the dual antiplatelet treatment
eriod, a median time of 6.3 months (3 to 15.8 months)
fter discontinuation of clopidogrel, and only 5 (7.1%)
ithin the first month.
Multivariate analysis was performed in a subgroup of 14,120
atients (Table 4). This subgroup was comparable in all ana-
yzed characteristics to the overall cohort. The independent
redictors for acute/subacute thrombosis were acute coronary
yndrome, ST-segment elevation myocardial infarction
STEMI), renal failure, stent in left anterior descending artery
LAD), stent length, and diabetes and for late thrombosis were
TEMI, stent in LAD, and stent length.
*p Value
Very Late ST
(n  62) †p Value ‡p Value
0.001 5 (8%) 0.038 0.0001
0.001 43 (69.3%) 0.32 0.0001
0.30 3 (4.8%) 0.96 0.69
0.80 1 (1.6%) 0.64 0.65
0.31 10 (16.1%) 0.66 0.094
0.25 5 (8%) 0.0006 0.007
0.002 15 (24.2%) 0.009 0.0001
nd/or ASA within the prescribed dual-therapy period; cessation of ASA monotherapy was the)
)
)
)
)
%)
%)
)
ogrel a
. †Late versus very late. ‡Acute/subacute versus very late.
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March 11, 2008:986–90 Nationwide Study on DES ThrombosisTable 5 summarizes the treatment and outcomes com-
aring the groups with acute/subacute and late ST. The
aplan survival analysis for the combined end point of death
nd recurrent thrombosis did not show significant differ-
nces between the groups (hazard ratio 1.2, 95% confidence
nterval 0.74 to 2.05, p  0.4). The independent predictors
or mortality and thrombosis recurrence after the ST event
re shown in Table 6.
iscussion
he use of DES in cardiology practice has been extended and
requently includes off-label indications. Hence, the incidence
f ST in real-world practice is not the same as that observed in
he trials. Iakovou et al. (3) found a 1.3% rate in 2,229 patients.
he group from Rotterdam reported 1% and 0.35% rates for
ngiographic subacute and late ST, respectively (4,5). The
ultivariate Analysis for Predictorsf ST in Subgroup o 14,120 Patients
Table 4 Multivariate Analysis for Predictorsof ST in a Subgroup of 14,120 Patients
Predictor Hazard Ratio 95% Confidence Interval p Value
Acute-subacute ST
ACS 2.6 1.3–4.9 0.0027
STEMI 6.9 4–12 0.0001
Renal failure 3.1 1.05–9.2 0.038
Diabetes 1.75 1.04–2.95 0.035
Stent length 1.08 1.06–1.1 0.0001
LAD 2.2 1.4–3.7 0.0011
Late ST
STEMI 5.2 5.5–7.6 0.0001
LAD 3.03 2.07–4.4 0.0001
Stent length 1.07 1.05–1.09 0.0001
bbreviations as in Table 1.
Clinical Presentation, Treatment, and Outcome
Table 5 Clinical Presentation, Treatment, an
Overall Sample
(n  301)
Presentation
STEMI 252 (83.7%)
Shock 62 (20.5%)
Basal TIMI flow grade 0 to 1 265 (88%)
Treatment
PCI 283 (94%)
Thrombectomy 110 (39%)
New stent 139 (49%)
Abciximab 187 (66%)
Post-PCI TIMI flow grade 3 238 (84%)
Outcome
In-hospital
Death 35 (11.6%)
Thrombosis 5 (1.66%)
Follow-up 261 (98%)
Time, months 11.8  10
Death 48 (16%)
Thrombosis 14 (4.6%)Values are mean  standard deviation or n (%).
PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocarroup from the Washington Hospital Center observed a rate of
.27% in 2,794 patients with renal failure, bifurcation, in-stent
estenosis, and clopidogrel discontinuation as independent
redictors (6). Finally, the Bern-Rotterdam registry yielded a
umulative incidence of 2.9% at 3 years in 8,146 patients (8).
iabetes and acute coronary syndrome were identified as
ndependent predictors.
redictors for late ST. Similar to our results, the registries
ited above noted that early discontinuation of antiplatelet
herapy was a relatively common finding in patients with
ate ST (3–6,8). The association of STEMI with late ST
as been noted in other clinical registries. The Rotterdam
roup reported a 2-year incidence of 3.2% for angiographic
hrombosis in 812 STEMI patients treated with DES (9).
onversely, the recently published randomized trials
howed no differences in thrombosis at 1 year between BMS
nd DES (10,11).
The LAD stent location had been observed, well over a
ecade ago, as a predictor for ST (12). A review of all
tcome
cute/Subacute ST
(n  149)
Late ST
(n  152) p Value
128 (86%) 124 (81.5%) 0.36
31 (21%) 31 (20.4%) 0.98
137 (92%) 128 (84.2%) 0.056
145 (97%) 138 (90.7%) 0.042
44 (30%) 66 (47.8%) 0.002
70 (48%) 69 (50%) 0.82
99 (68%) 88 (63.7%) 0.50
126 (87%) 112 (81.1%) 0.20
20 (13%) 15 (9.8%)
4 (2.7%) 1 (0.66%)
128 (99%) 133 (97%)
15  11 8.8  7.6
28 (18.8%) 20 (13.1%)
9 (6%) 5 (3.3%)
ndependent Predictors forortality and R current Thrombosis
Table 6 Independent Predictors forMortality and Recurrent Thrombosis
Predictor
Hazard
Ratio
95% Confidence
Interval p Value
Predictors of mortality
Post-PCI TIMI flow grade 3 13 4.3–39 0.0001
Age 1.09 1.04–1.15 0.0001
New stent 4.04 1.36–12 0.012
LVEF 45% 2.66 1.01–7 0.047
Predictors of recurrent thrombosis
Abciximab administration 0.17 0.04–0.65 0.018
New stent 5.08 1.07–24 0.040
VEF  left ventricular ejection fraction; other abbreviations as in Table 5.d Ou
Adial Infarction; other abbreviations as in Table 1.
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Nationwide Study on DES Thrombosis March 11, 2008:986–90ublished case reports of late stent thrombosis shows that
4% of them had had DES implanted in the LAD ar-
ery (13). The LAD location in our study was frequently
ssociated with a recent history of infarction in this territory.
ES versus BMS thrombosis. Our registry uses angio-
raphic documentation of ST and certainly underestimates
he real incidence of ST. The overall incidence of DES-
ssociated documented thrombosis results are slightly
igher than reported previously with BMS (14,15). A rate
f 0.6% to 0.8% for late-onset thrombosis with BMS has
een reported (16); however, these events occurred very
xceptionally 12 months post-procedure in the absence of
rior brachytherapy.
reatment and clinical outcome. The implantation of an
dditional stent was associated with an adverse outcome,
hereas the infusion of abciximab reduced the recurrence of
T episodes. The use of new stents should be restricted to
hose with significant residual stenosis after balloon dilata-
ion or with stent-edge dissections. The use of intravascular
ltrasound could identify predisposing mechanical factors
nd could help guide interventions. In fact, detailed intra-
ascular ultrasound studies of 12 of these patients with
onfirmed DES thrombosis have been previously
eported (17).
tudy limitations. This is the largest registry available to
ate addressing DES thrombosis; however, several limita-
ions should be noted. The study is observational in nature
nd has inherent disadvantages. This is a registry of angio-
raphically documented (definite) thrombosis, and as such,
he rates of DES are underestimated. The ST incidence
ould have been closer to reality if we had included
robable and possible ST cases (18). However, we felt that
lear, clinical, angiographic and procedural characteristics of
T patients were appropriate in defining the profile and
ariables associated. The multivariate analysis was con-
ucted in a subgroup of patients within the overall cohort;
evertheless, this was a clearly representative group, being
he largest multivariate analysis available to date in the
iterature. Finally, as in other registries (8), it was not
ossible to ascertain retrospectively the compliance with
ntiplatelet treatment in patients without ST.
onclusions
n this multicenter registry of DES, the cumulative inci-
ence of angiographically documented stent thrombosis was
% at 3 years. No differences were found between paclitaxel-
luting and sirolimus-eluting stents. The profiles of patients
ith early and late thrombosis were different. The short-
erm prognosis is poor, especially when the restoration of
ormal flow has failed.
1eprint requests and correspondence: Dr. José M. de la Torre
erna´ndez, Unidad de Hemodina´mica y Cardiologı´a Intervenci-
nista, Hospital Universitario Marqués de Valdecilla, Avda.
aldecilla s/n, 39008 Santander, Spain. E-mail: he1thj@humv.es.
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